LeMaitre Vascular, Inc. (LMAT)

Market Cap	1.87B -2.1%
Revenue (ttm)	262.43M +11.8%
Net Income	65.67M +39.4%
EPS	2.86 +39.4%
Shares Out	22.87M
PE Ratio	28.82
Forward PE	26.94
Dividend	$1.00 (1.21%)
Ex-Dividend Date	Aug 20, 2026

Volume	34,196
Open	82.13
Previous Close	82.34
Day's Range	81.25 - 82.13
52-Week Range	78.22 - 118.01
Beta	0.49
Analysts	Buy
Price Target	107.00 (+31.15%)
Est. Earnings	Nov 5, 2026

About LMAT

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheter...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Oct 19, 2006
• Employees: 655
• Stock Exchange: NASDAQ
• Ticker Symbol: LMAT
• Website: https://www.lemaitre.com

Financial Performance

In 2025, LeMaitre Vascular's revenue was $249.60 million, an increase of 13.53% compared to the previous year's $219.86 million. Earnings were $57.73 million, an increase of 31.10%.

Analyst Summary

According to 8 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price target is $107.0, which is an increase of 31.15% from the latest price.

Price Target

$107.0

(31.15% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Sep 29, 2026

Data Sources Report a data error